FEB 24, 2020 8:50 PM PST

Leukemic Drugs May Target Lung Cancer

WRITTEN BY: Nouran Amin

Two approved therapeutics for treating leukemia are currently being investigated for treatment-resistant lung cancer.  The findings were based on a live cell method developed to identify small molecules that target specific mutations in cancer cells.

Learn more about lung cancer:

"Drug resistance is a big problem for lung cancer patients," says Igor Stagljar, a professor of molecular genetics and biochemistry at the Donnelly Centre for Cellular and Biomolecular Research. "Our new technology allows us to find molecules that could be used against cancers for which no other treatment options are available."

The drugs used in the study are gilteritinib and midostaurin which have been previously approved to treat a particular form of leukemia. Now, these drugs could treat highly resistant lung cancer patients with triple mutant epidermal growth factor receptor (EGFR).

"We already have a sense of gilteritinib doses that are safe to give to humans," says Dr. Adrian Sacher, an oncologist at Toronto's Princess Margaret Cancer Centre, at University Health Network, who will lead the trial. "We only need to demonstrate efficacy and hopefully make them a novel treatment option for lung cancer patients that have developed resistance to current targeted therapies."

Learn more about treatment-resistant lung cancer:

Findings were published in Nature Chemical Biology.

"The advantage of our method is that we are doing it in living cells, where we have all the other molecular machineries present that are important for signal transduction," says Stagljar. "Also, the compounds are fished at very low dose, which allows us to test for both permeability and toxicity at the same time."

"The unbiased screening approach by the Stagljar's group has the merit of identifying small molecule inhibitors that could act via new mechanisms of action that would otherwise escape detection by conventional drug development strategies, as shown in this proof of principle study, " says Marino Zerial, Managing Director of the Max Planck Institute of Molecular Cell Biology and Genetics in Dresden, Germany and one of Stagljar's collaborators.

Source: Science Daily

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
FEB 02, 2020
Microbiology
FEB 02, 2020
A Potential Treatment for MERS is Found
A coronavirus causes MERS, which currently has no treatment. This work may help change that....
FEB 21, 2020
Drug Discovery & Development
FEB 21, 2020
Why is it so Difficult to Develop a Vaccine for Coronavirus?
As of February 21st, 2,250 have died worldwide from Coronavirus, while 18,862 have recovered and 55,703 are currently infected. Having made top news storie...
MAR 08, 2020
Cancer
MAR 08, 2020
New treatment for triple-negative breast cancer
A new study led by scientists at the University of Sussex suggests an alternative treatment strategy for patients diagnosed with triple-negative breast can...
MAR 06, 2020
Drug Discovery & Development
MAR 06, 2020
Scorpion-derived Proteins Deliver Arthritis Treatment
New research published in the journal Science Translational Medicine shows that that a scorpion-derived proteins could soon provide relief for arthritis. &...
MAR 29, 2020
Cancer
MAR 29, 2020
Improving ependymoma diagnostics
Have you ever heard of ependymoma? This rare form of brain cancer most commonly occurs in young children when tumors form from ependymal cells in the brain...
APR 04, 2020
Cancer
APR 04, 2020
Unique Cancer Mutation Hijacks Nearby Signaling Pathway
  In cancer, tyrosine kinase mutations are quite common. MET is one such example that normally binds its native ligand, hepatocyte growth factor...
Loading Comments...